• IMMUNE NETWORK
• /
• v.7 no.1
• /
• pp.31-38
• /
• 2007

Background: Mizoribine (MZR) is an imidazole nucleoside isolated from Eupenicillium brefeldianum. MZR is currendy in clinical use for patients who have undergone renal transplantation. Therapeutic efficacy of MZR has also been demonstrated in rheumatoid arthritis and lupus nephritis. MZR has been shown to inhibit the proliferation or lymphocytes by interfering with inosine monophosphate dehydrogenase. Since the exact mechanism by which MZR benefits rheumatoid arthritis (RA) is not clear, we investigated the ability of MZR to direct its immunosuppressive influences on other antigen presenting cells, such as macrophages. Methods: Mouse macrophage RAW264.7 cells were stimulated with lipopolysaccharide in the presence of MZR. To elucidate the mechanism of the therapeutic efficacy in chronic inflammatory diseases, we examined the effects of MZR on the production of pro-inflammatory cytokines, nitric oxide (NO) and prostaglandin $E_2\;(PGE_2)$ in macrophages. Results: MZR dose-dependendy decreased the production of nitric oxide and pro- inflammatory cytokines such as tumor necrosis factor-${\alpha}$ (TNF-${\alpha}$), interleukins $1{\beta}$ (IL-${\beta}$ and IL-6 $PGE_2$. Examination of gene expression levels showed that the anti-inflammatory effect correlated with the down-regulation of inducible nitiric oxide synthase expression, cycloxygenase-2 expression and TNF-${\alpha}$ gene expression. Conclusion: In this work, we resulted whether MZR $(1.25{\sim}10{\mu}g/ml)$ inhibited macrophage activation by inhibiting secretion of pro-inflammatory cytokines, NO and $PGE_2$. These findings provide an explanation for the therapeutic efficacy of MZR in chronic inflammation-associated diseases.

• Biomolecules & Therapeutics
• /
• v.5 no.2
• /
• pp.187-193
• /
• 1997

The in vivo and in vivo antibacterial activity of DW-116, a newly synthesized fluoroquinolone, were compared with those of other quinolones. DW-116 exhibited more potent antibacterial activity than rufloxacin and lower activity than ofloxacin and ciprofloxacin in in vivo assay But, DW-116 particularly showed strong activity against the family of staphylococci including methicillin-sensitive staphylococcus and its activity was more active than that of ciprofloxacin. The time-kill curve studies showed rapid bactericidal activity for DW-116. The post-antibiotic effect of DW-116 was observed between 0.66 and 5 hours. The therapeutic efficacy of DW-116 against respiratory infection with P. aeruginosa was as strong as that of ciprofloxacin and its effect against urinary tract in(traction with E. coli was more effective than rufloxacin. The excellent therapeutic efficacy of DW-116 against these local infections is due to its good pharmacokinetic profiles.

• IMMUNE NETWORK
• /
• v.9 no.5
• /
• pp.179-191
• /
• 2009

Background: The present study examines a hypothesis that short allergen-derived peptides may shift an Aspergillus fumigatus (Afu-) specific TH2 response towards a protective TH1. Five overlapping peptides (P1-P5) derived from Asp f1, a major allergen/antigen of Afu, were evaluated for prophylactic or therapeutic efficacy in BALB/c mice. Methods: To evaluate the prophylactic efficacy, peptides were intranasally administered to naive mice and challenged with Afu-allergens/antigens. For evaluation of therapeutic efficacy, the mice were sensitized with Afu-allergens/antigens followed by intranasal administration of peptides. The groups were compared for the levels of Afu-specific antibodies in sera and splenic cytokines evaluated by ELISA. Eosinophil peroxidase activity was examined in the lung cell suspensions and lung inflammation was assessed by histopathogy. Results: Peptides P1-, P2- and P3 decreased Afu-specific IgE (84.5~98.9%) and IgG antibodies (45.7~71.6%) in comparison with Afu-sensitized mice prophylactically. P1- and P2-treated ABPA mice showed decline in Afu-specific IgE (76.4~88%) and IgG antibodies (15~54%). Increased IgG2a/IgG1 and IFN-${\gamma}$/IL-4 ratios were observed. P1-P3 prophylactically and P1 therapeutically decreased IL-5 levels and eosinophil peroxidase activity. P1 decreased inflammatory cells' infiltration in lung tissue comparable to non-challenged control. Conclusion: Asp f1-derived peptide P1, prophylactically and therapeutically administered to Balb/c mice, is effective in regulating allergic response to allergens/antigens of Afu, and may be explored for immunotherapy of allergic aspergillosis in humans.

• Journal of Physiology & Pathology in Korean Medicine
• /
• v.21 no.2
• /
• pp.518-522
• /
• 2007

The cortex and root of Acnthopanax sessiliflorus, a herbal medicine, have been used for several diseases including cancer in Oriental countries. In the previous study, we showed that the cortex of this plant have anti-cancer activity. But its therapeutic efficacy of CORTEX ACANTHOPANAX RADICIS (CAR) is not clarified. For these reasons, we investigated immuno-potentiating and anti-cancer properties of CAR compared with CA, in terms of body and tumor weights, proliferation of thymocytes and tumor cells, and nitric oxide production from macrophages through in vitro and in vivo studies. In our results, administration of CAR reduced tumor mass and increased body weights. CAR also inhibited proliferation of tumor cells in vivo and in vitro dose-dependently. Thymocyte proliferation was accelerated by treatment with CAR and NO production was also promoted by CAR in vivo and vitro. In conclusion, we demonstrated that CAR is useful to treat for cancer as complementary or alternative medicine to Western medication, its therapeutic efficacy is involved in direct inhibition of tumor growth and immuno-potentiating activity.

• Journal of Veterinary Science
• /
• v.23 no.5
• /
• pp.78.1-78.13
• /
• 2022

Background: Florfenicol might be ineffective for treating Staphylococcus aureus small colony variants (SCVs) mastitis. Objectives: In this study, florfenicol-loaded chitosan (CS)-sodium tripolyphosphate (TPP) composite nanogels were prepared to allow targeted delivery to SCV infected sites. Methods: The formulation screening, the characteristics, in vitro release, antibacterial activity, therapeutic efficacy, and biosafety of the florfenicol composite nanogels were studied. Results: The optimized formulation was obtained when the CS and TPP were 10 and 5 mg/mL, respectively. The encapsulation efficiency, loading capacity, size, polydispersity index, and zeta potential of the optimized florfenicol composite nanogels were 87.3% ± 2.7%, 5.8% ± 1.4%, 280.3 ± 1.5 nm, 0.15 ± 0.03, and 36.3 ± 1.4 mv, respectively. Optical and scanning electron microscopy showed that spherical particles with a relatively uniform distribution and drugs might be incorporated in cross-linked polymeric networks. The in vitro release study showed that the florfenicol composite nanogels exhibited a biphasic pattern with the sustained release of 72.2% ± 1.8% at 48 h in pH 5.5 phosphate-buffered saline. The minimal inhibitory concentrations of commercial florfenicol solution and florfenicol composite nanogels against SCVs were 1 and 0.25 ㎍/mL, respectively. The time-killing curves and live-dead bacterial staining showed that the florfenicol composite nanogels were concentration-dependent. Furthermore, the florfenicol composite nanogels displayed good therapeutic efficacy against SCVs mastitis. Biological safety studies showed that the florfenicol composite nanogels might be a biocompatible preparation because of their non-toxic effects on the renal tissue and liver. Conclusions: Florfenicol composite nanogels might improve the treatment of SCV infections.

• Clinical and Experimental Pediatrics
• /
• v.45 no.4
• /
• pp.473-481
• /
• 2002

Purpose : Ascending cholangitis is the most common complication after Kasai operations. The aim of this study is to evaluate the therapeutic efficacy of cefotaxime as an empirical antibiotic on ascending cholangitis after Kasai operations. Methods : Thirty-nine episodes of cholangitis in twenty-nine children who underwent Kasai operations at Seoul National University Children's Hospital from January 1991 to December 2000 were included in this study. Empirical cefotaxime treatments were divided into three groups : cefotaxime and amikacin treatment group(CA group), cefotaxime and gentamicin treatment group(CG group) and cefotaxime treatment group(C group). A diagnosis of cholangitis was made on the basis of unexplained fever(>$38^{\circ}C$) and either development of acholic stool or elevation of serum total bilirubin (>1.5 mg/dL). Therapeutic efficacy was judged by elimination of fever up to 72 hours, 120 hours, and 168 hours after antibiotic treatment. Results : There were therapeutic responses in 51%(20/39) up to 72 hours after antibiotic treatment : 54%(13/24) in CA group, 43%(3/7) in CG group and 50%(4/8) in C group. There were therapeutic responses in 69%(27/39) up to 120 hours, in 79%(31/39) up to 168 hours and in 82%(32/39) up to 2 weeks. There were no differences in therapeutic efficacy among the three regimens. In 12 of 39 episodes, the etiologic pathogens including Escherichia coli and enterococcus were cultured from the blood. Conclusion : Cefotaxime can be tried as an initial antibiotic in Korean children with ascending cholangitis after Kasai operation prior to the identification of microorganism on culture. However, further evaluation of pathogen and its resistant strain to cefotaxime should be done.

• The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology
• /
• v.1 no.1
• /
• pp.73-81
• /
• 1988

The study was clinically performed in the 65 outpatients with pruritus who visited the Dept. of Dermatology, Oriental Medicial Hospital, Kyung Hee University and oriental medical clinic of Hang Ki Park from Jan. 1985 through Dec. 1986. The results were summarized as follows: 1. Among 65 outpatients, male was 20 ($30.8\%$) and female was 45 ($69.2\%$). In the distribution of age, 10S was $21.5\%,\;and\;20S\;20\%$ at the first visit. 2. In the distribution of season, the peak incidence occured in Spring ($35.4\%$) and next incidence in Winter ($20\%$). 3. In the distribution of duration, $41.5\%$ was between 1 year and 5 years, $20\%$ between 1 month and 6 months, $12.3\%$ between 6 months and 1 year, $9.2\%$ between 5 years and 10 years, $7.7\%$ over 10 years. 4. In regard to the itching lesion, $66.2\%$ showed pruritus throughout the whole body, including partially $15.4\%$ in their heads and faces, $12.3\%$ in their hands and legs, and $6.3\%$ in their shoulders, sides and hips. 5. The most frequently used prescription, was Gosanhomasan (苦蔘胡麻散) which occupied $60.7\%$ of all, in next order of frequency, Gamisamooltang (加味四物湯 $21.4\%$) Gupoongchongkisan (祛風淸肌散 $12.5\%$) and Bangpoongtongsungsan (防風通聖散 $5.4\%$). 6. In regard to the therapeutic duration, $46.2\%$ was showed under 10 days, $18.5\%$ between 10 days and 20 days, and $16.9\%$ between 30 days and 60 days. 7. In the 35 patients, who were confirmed to show apparent result by continual treatment, curative rate was more than $57.6\%$. According to above results, we can confirm that efficacy of therapeutic measures by the oriental medicine on pruritic dermatoses was increased in proportion to therapeutic duration and we feel sure that the therapeutic efficacy can be gradually increased as we expect to make a deep study of the disease and to give correct medical treatment to the nature of the disease.

• Korean Journal of Otorhinolaryngology-Head and Neck Surgery
• /
• v.61 no.12
• /
• pp.658-662
• /
• 2018

Background and Objectives The early assessment of treatment is not done for benign paroxysmal positional vertigo (BPPV) since the well-known phenomenon of fatigability after a repeated positional test can mimic successful treatment. The aim of this study is to evaluate the clinical implication of 'fatigability' after Epley maneuver and to identify the therapeutic efficacy of Epley maneuver in posterior canal BPPV (PC-BPPV). Subjects and Method This study was prospectively conducted by two dizziness clinics on 51 consecutive patients diagnosed with PC-BPPV. All patients included in the study received Epley maneuver treatment. The therapeutic results were reassessed immediately after a single trial of Epley maneuver. After 30 minutes, results were reassessed repeatedly to confirm the fatigability of diagnostic procedure immediately after treatment. If the treatment was not successful after 30 minutes, Epley maneuver was repeatedly performed until complete resolution. Results Immediately after the first maneuver, 45 of 51 (88.2%) patients had neither vertigo nor nystagmus during the positional test. All patients demonstrated complete resolution after receiving one to three Epley maneuvers on the day of diagnosis. 'Fatigability (false negative result)' was confirmed for only one case (1 of 6 patients, 16.7%), in which nystagmus was observed after 30 minutes but not identified immediately after the first Epley maneuver. Conclusion The therapeutic efficacy of Epley maneuver is very high in PC-BPPV. Considering the possibility of fatigability when reassessment is performed immediately after therapeutic maneuver, clinicians should avoid assessing the outcome immediately after treatment in patients with PC-BPPV.

• Journal of Korean Physical Therapy Science
• /
• v.8 no.1
• /
• pp.869-877
• /
• 2001

This study was performed to assess the efficacy of Kinesiotape for the frozen shoulder patients. The subjects of this study were 17 patients with frozen shoulder who visited the out-patient department of the physical therapy, Pyongchon Sacret Heart Hospital, Hallim University, from July. 3, 2000 through August 12, 2000. To find out the effect of kinesiotape therapy, we sampled 8 patients treated with electrotherapy and therapeutic exercise (control group), and 9 patients treated with electrotherapy and therapeutic exercise with kinesiotape(experimental group). All patients were treated 3 days a week for 5 weeks. The results after 5-week treatment, compared with before treatment, were as follows: 1. The increase in range of motion in the electrotherapy and therapeutic exercise with kinesiotape after 5-week treatment was very significant(p<0.01). 2 The increase in range of motion in the electrotherapy and therapeutic exercise after 5-week treatment was significant (p<0.05). 3. The pain of decrease in the electrotherapy and therapeutic exercise with kinesiotape after 5-week treatment was very significant (p<0.01). 4. The pain of decrease in the electrotherapy and therapeutic exercise with kinesiotape 5-week treatment was significant(p<0.05). 5. The electrotherapy and therapeutic exercise with kinesiotape was more effective in increasing the range of motion on shoulder than the electrotherapy and therapeutic exercise after 5-week treatment(p<0.01). 6. The pain of decrease in between electrotherapy. therapeutic exercise with kinesiotape electrotherapy and therapeutic exercise after 5-week treatment was no significant.

• Biomolecules & Therapeutics
• /
• v.22 no.3
• /
• pp.260-266
• /
• 2014

This study evaluated the pharmacokinetic profile and therapeutic efficacy of piroxicam (PX), a long acting non-steroidal anti-inflammatory drug for the treatment of arthritis, following intra-articular (IA) injection in comparison to the pharmacokinetic profile and therapeutic efficacy of PX after intramuscular (IM) injection. In the pharmacokinetic study in rats, systemic exposure and pharmacokinetic parameters of PX after a single IA dose were compared with systemic exposure and pharmacokinetic parameters of PX after administration of the same dose IM (0.6 mg/kg). The anti-inflammatory and analgesic effects of IA PX were evaluated simultaneously in a monoiodoacetate-induced osteoarthritis rat model. The plasma PX concentration rapidly rose following IA injection, and it was comparable to the plasma PX concentration following IM injection, suggesting the rapid efflux of the drug molecule from the joint cavity. However, in the efficacy study, the IA PX administration significantly reduced the knee swelling by reducing the level of prostaglandin $E_2$ in the joint, compared to that following administration of IA vehicle and after administration of the IM PX dose. In addition, we found that the anti-inflammatory and anti-nociceptive efficacies of IA PX were synergistically increased upon co-treatment with hyaluronic acid (HA), a potent agent for the treatment of osteoarthritis, at the weight ratio of 1:1 or 1:2, and these effects were more pronounced than those following administration of HA or PX alone. In conclusion, this study demonstrated the efficacy of the IA use of PX alone and/or in combination with HA in osteoarthritis.